Thoratec gets study boost for new-generation heart pump
This article was originally published in Clinica
Thoratec saw its share price jump last week, after a pivotal US trial of its HeartMate II device showed that the next-generation heart pump provided reliable, long-term support in patients awaiting a heart transplant, and improve their quality of life.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.